Q4 2026 3B Blackbio DX Ltd Earnings Call Transcript

Jun 1, 2026 / 10:30 AM GMT

Release Date Price: ₹1105.25 (-11.16%)

Transcript

Key Points

Positve

3B BlackBio Dx Ltd (BOM:532067) reported a strong year with consolidated revenue of approximately 142 crore INR and a PAT of nearly 160 crores.
The molecular diagnostic business in India grew by approximately 10%, with sales increasing from 78.34 crores to 86.47 crores.
TruePCR Europe showed consistent growth with a 40% increase over the last four years, reaching sales of GBP1.75 million in FY26.
The acquisition of Chorus BioConcert contributed significantly to consolidated revenue and profitability, with sales of Rs 35.91 crore and a PAT of Rs 8.76 crore.
The company is optimistic about future growth, targeting a 15% to 20% increase in revenue for FY27, driven by global expansion and strategic partnerships.

Negative

Growth in the Indian molecular diagnostic business was slightly lower than projections due to exceptional flu and chikungunya demand in FY25 and geopolitical tensions in the Middle East.
The standalone revenue growth has slowed down to 2% to 3% YOY for the last two quarters, compared to previous strong growth rates of 15% to 20%.
Increased competition from small players and multinational companies in niche markets like oncology and tuberculosis.
The US FDA approval process for AMR products is ongoing, with uncertainty around the timeframe for successful clearance.
Chorus BioConcert faces competition from Chinese companies offering low rates for respiratory and entero products, impacting growth and profitability.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

3BBL.NS - 3B Blackbio DX Ltd
Q4 2026 3B Blackbio DX Ltd Earnings Call
Jun 01, 2026 / 10:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to 3B Black Bio DX Limited's Q4 FY26 Results Conference Call hosted by Nuvama Wealth and Investment Limited.

As a reminder, all biosplinines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing then zero on your touch phone. Please. Please note that this conference is being recorded.

I now hand the conference over to Mr. Ranveer Singh from Nuvama Wealth and Investment Limited.

Thank you and over to you, Mrs. Singh.

--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.